Kernt Marcus, Neubauer Aljoscha Steffen, Ulbig Michael W, Kampik Anselm, Welge-Lüssen Ulrich
Department of Ophthalmology, Ludwig-Maximilians-Universität, Munich, Germany.
J Cataract Refract Surg. 2008 Mar;34(3):480-8. doi: 10.1016/j.jcrs.2007.10.046.
To investigate the safety of moxifloxacin for intravitreal application in a cell culture model.
Department of Ophthalmology, Ludwig-Maximilians-Universität, Munich, Germany.
Primary human retinal pigment epithelium (RPE) cells, ARPE19 cells, and primary optic nerve head astrocyte (ONHA) cells were treated with concentrations of moxifloxacin ranging from 10 to 750 microg/mL. Possible toxic effects and median inhibitory concentration were evaluated after 24 hours as well as under conditions of oxidative stress. After treating the RPE and ONHA cell lines with tumor necrosis factor-alpha (TNF-alpha; 10 microg/mL), lipopolysaccharides (LPS; 20 microg/mL), and interleukin-6 (IL-6; 20 microg/mL), the effects of moxifloxacin on cellular viability under conditions of inflammation were investigated. Toxicity was evaluated by measuring the inhibition of RPE cell proliferation with the tetrazolium dye-reduction assay (MTT; 3-[4,5-dimethylthiazol- 2-yl]-2,5-diphenyl tetrazolium bromide). Cell viability was quantified by a microscopic live/dead assay.
At concentrations higher than 150 microg/mL, moxifloxacin had adverse effects on primary RPE, ARPE19, and ONHA cell proliferation and viability. Lower concentrations did not affect RPE or ONHA cell proliferation and viability when administered for 24 hours. No significant decrease in proliferation and viability was observed after preincubation with TNF-alpha, LPS, and IL-6 for 24 hours and subsequent treatment with moxifloxacin concentrations of 10 to 150 microg/mL for 24 hours. Hydrogen peroxide exposure did not increase cellular toxicity.
No significant toxicity of moxifloxacin was seen on primary RPE cells, ARPE19 cells, or ONHA cells at concentrations up to 150 microg/mL. Intravitreal use of moxifloxacin up to this concentration may be safe and effective for the treatment of endophthalmitis.
在细胞培养模型中研究玻璃体内应用莫西沙星的安全性。
德国慕尼黑路德维希 - 马克西米利安大学眼科。
用浓度范围为10至750微克/毫升的莫西沙星处理原代人视网膜色素上皮（RPE）细胞、ARPE19细胞和原代视神经乳头星形胶质细胞（ONHA）。在24小时后以及氧化应激条件下评估可能的毒性作用和半数抑制浓度。在用肿瘤坏死因子 -α（TNF -α；10微克/毫升）、脂多糖（LPS；20微克/毫升）和白细胞介素 -6（IL -6；20微克/毫升）处理RPE和ONHA细胞系后，研究莫西沙星在炎症条件下对细胞活力的影响。通过用四唑盐染料还原试验（MTT；3 - [4,5 - 二甲基噻唑 -2 - 基] -2,5 - 二苯基溴化四氮唑）测量RPE细胞增殖抑制来评估毒性。通过显微镜下活/死试验对细胞活力进行定量。
浓度高于150微克/毫升时，莫西沙星对原代RPE、ARPE19和ONHA细胞增殖及活力有不良影响。给药24小时时，较低浓度不影响RPE或ONHA细胞增殖及活力。在用TNF -α、LPS和IL -6预孵育24小时，随后用浓度为10至150微克/毫升的莫西沙星处理24小时后，未观察到增殖和活力有显著下降。过氧化氢暴露未增加细胞毒性。
浓度高达150微克/毫升时，莫西沙星对原代RPE细胞、ARPE19细胞或ONHA细胞未见明显毒性。玻璃体内使用该浓度以下的莫西沙星治疗眼内炎可能安全有效。
